12: Dealcast: Allergan reaction

episode

Dealcast: The M&A Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A.I. Safety Goes Mainstream + a ‘Hard Fork’ Exit AMA 1h 25m · 18 Sep 2026 · Hard Fork

Layoffs at the Kansas City Star will hurt local communities 15 min · 18 Sep 2026 · Kansas City Today

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Win Brooke's Bucks (9/17/26) 11 min · 17 Sep 2026 · Brooke and Jeffrey

TikTok Click Shock (9/17/26) 12 min · 17 Sep 2026 · Brooke and Jeffrey

Dancing With The Semi-Stars: Thursday, September 17th, 2026 1h 21m · 17 Sep 2026 · The Toast

Report any issue

Source

Recorded09 Aug 2019

Publisherfast.wistia.com ↗

Handlerec:6530535

Show notes

The European Commission (EC) is reviewing AbbVie’s [NYSE:ABBV] proposed acquisition of Botox producer Allergan [NYSE:AGN]. The merging parties have already pledged to divest such products as brazikumab, a drug under development for ulcerative colitis and Crohn’s disease, and Zenpep (pancrelipase), which treats a pancreatic disorder, but the EC may want more changes if it is to approve the deal. Dealreporter’s Pablo Mayo Cerqueiro and Mergermarket’s Mintoi Chessa-Florea joined us to discuss how the EC’s review is likely to go.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in